ES2148525T3 - Inmunomoduladores. - Google Patents

Inmunomoduladores.

Info

Publication number
ES2148525T3
ES2148525T3 ES95920796T ES95920796T ES2148525T3 ES 2148525 T3 ES2148525 T3 ES 2148525T3 ES 95920796 T ES95920796 T ES 95920796T ES 95920796 T ES95920796 T ES 95920796T ES 2148525 T3 ES2148525 T3 ES 2148525T3
Authority
ES
Spain
Prior art keywords
human
production
induces
monocites
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95920796T
Other languages
English (en)
Inventor
Larsen Christian Gronhoj
Borbala Gesser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Steeno Research Group AS
Original Assignee
Steeno Research Group AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steeno Research Group AS filed Critical Steeno Research Group AS
Application granted granted Critical
Publication of ES2148525T3 publication Critical patent/ES2148525T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN POLIPEPTIDO DISTINTO A INTERLEUCINA HUMANA (10) EL CUAL TIENE AL MENOS UNA DE LAS SIGUIENTES PROPIEDADES: A) INDUCE A INHIBICION DE PRODUCCION DE IL-8 ESPONTANEA MEDIANTE MONOCITOS HUMANOS, B) INDUCE A INHIBICION DE PRODUCCION DE IL-8 DE IL-1{BE} INDUCIDA MEDIANTE CELULAS MONONUCLEARES SANGUINEAS PERIFERICAS HUMANAS (PBMC), C) INDUCE A PRODUCCION DE LA PROTEINA ANTAGONICA DEL RECEPTOR DE INTERLEUCINA-1 (IRAP) MEDIANTE MONOCITOS HUMANOS, D) INDUCE A LA MIGRACION QUIMIOTACTICA DE LINFOCITOS T HUMANOS CD8+ IN VITRO, E) DESENSIBILIZA CELULAS T CD8+ HUMANAS DANDO COMO RESULTADO UNA FALTA DE RESPUESTA HACIA RHIL-10, F) SUPRIME LA RESPUESTA QUIMIOTACTICA DE LINFOTITOS HUMANOS T CD4+ HACIA IL-8, G) SUPRIME LA RESPUESTA QUIMIOTACTICA DE MONOCITOS HUMANOS HACIA MCAF/MCP-1, H) NO INHIBE LA EXPRESION MOLECULAR MHC DE CLASE II EN MONOCITOS HUMANOS, EN CONTRASTE CON IL-10 HUMANO, I) INDUCE A LA PRODUCCION DE IL-4 MEDIANTE CELULAS T CD4+ HUMANAS NORMALES CULTIVADAS, J) REDUCE LA PRODUCCION DE TNF{AL} EN REACCION DE LEUCOCITO MIXTO HUMANO. EN PARTICULAR, LA INVENCION SE REFIERE AL NONAPEPTIDO ALA-TYR-MET-THR-MET-LYS-ILE-ARG-ASN Y ANALOGOS Y VARIANTES DEL MISMO.
ES95920796T 1994-07-05 1995-06-07 Inmunomoduladores. Expired - Lifetime ES2148525T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK80094 1994-07-05

Publications (1)

Publication Number Publication Date
ES2148525T3 true ES2148525T3 (es) 2000-10-16

Family

ID=8097707

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95920796T Expired - Lifetime ES2148525T3 (es) 1994-07-05 1995-06-07 Inmunomoduladores.

Country Status (28)

Country Link
US (3) US6159937A (es)
EP (2) EP1013764A1 (es)
JP (1) JPH10502249A (es)
CN (1) CN1216992C (es)
AP (1) AP690A (es)
AT (1) ATE195003T1 (es)
AU (1) AU686816B2 (es)
BR (1) BR9508243A (es)
CA (1) CA2194444C (es)
CZ (1) CZ1497A3 (es)
DE (1) DE69518156T2 (es)
DK (1) DK0769054T3 (es)
EE (1) EE03451B1 (es)
ES (1) ES2148525T3 (es)
FI (1) FI970009A (es)
GR (1) GR3034628T3 (es)
HK (1) HK1012416A1 (es)
HU (1) HU220344B (es)
MX (1) MX9606537A (es)
NO (1) NO970020L (es)
NZ (1) NZ287406A (es)
PL (1) PL181042B1 (es)
PT (1) PT769054E (es)
RO (1) RO118758B1 (es)
RU (1) RU2218348C2 (es)
SK (1) SK283096B6 (es)
UA (1) UA57702C2 (es)
WO (1) WO1996001318A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9403526D0 (sv) 1994-10-14 1994-10-14 Astra Ab New Peptides
SE9501067D0 (sv) 1995-03-24 1995-03-24 Astra Ab New peptides
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
EP0906117A1 (en) * 1996-05-02 1999-04-07 Schering Corporation Method for treating or preventing ischemia-reperfusion injury
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
SE9603468D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
SE9603463D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
US6086868A (en) * 1997-04-30 2000-07-11 Schering Corporation Method for treating or preventing ischemia-reperfusion injury
AU9449398A (en) * 1997-10-10 1999-05-03 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
CA2356010A1 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
DE60019104D1 (de) * 1999-05-25 2005-05-04 Canji Inc Gentherapy von lungenkrankheiten
US20020183271A1 (en) * 2000-12-07 2002-12-05 Sunil Chada Methods of treatment involving human MDA-7
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
US20040086896A1 (en) * 2001-04-19 2004-05-06 Julie Carman Polynucleotides and polypeptides associated with the NF-kB pathway
BR0307691A (pt) * 2002-02-11 2005-01-11 Arkion Life Sciences Composição, fator de inibição de citocina purificado e seu método de purificação, método de inibição da expressão de citocina e método para modular o sistema imunológico de um animal
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US8329169B2 (en) * 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US20050164244A1 (en) * 2003-10-23 2005-07-28 David Glass Methods of determining juvenile arthritis classification
CA2548220A1 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
WO2005087793A2 (en) 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
WO2006063028A2 (en) * 2004-12-07 2006-06-15 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
GB0500643D0 (en) * 2005-01-13 2005-02-23 Renovo Ltd Medicaments
JP2008531481A (ja) * 2005-02-08 2008-08-14 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 癌の治療のための、ｍｄａ−７を含む組成物および方法
WO2006119170A2 (en) * 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
ES2696824T3 (es) 2005-05-31 2019-01-18 Univ Colorado Regents Métodos para suministrar genes
AU2007263265A1 (en) * 2006-06-21 2007-12-27 Apogenix Gmbh Differential IL-4 and/or IL-10 cytokine expression in human cancer
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
US8460697B2 (en) * 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
USRE46425E1 (en) 2006-12-13 2017-06-06 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US7838497B2 (en) * 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
CN101391103B (zh) * 2008-07-31 2013-07-24 张可 一种预防和治疗艾滋病病毒感染的药物组合物
WO2010022227A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Methods for monitoring il-10 therapy
WO2011047097A2 (en) * 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
WO2012122985A1 (en) * 2011-03-14 2012-09-20 University Of Copenhagen Antagonists of the interleukin- 1 receptor
WO2013122544A2 (en) 2012-02-13 2013-08-22 Agency For Science, Technology And Research IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
US10512672B2 (en) 2013-07-18 2019-12-24 Xalud Therapeutics, Inc. Methods for the treatment of inflammatory joint disease
JP6140566B2 (ja) * 2013-07-31 2017-05-31 アイシン・エィ・ダブリュ株式会社 コイル装着方法及びコイル装着治具
CN105944086B (zh) * 2016-06-13 2017-08-25 浙江生创精准医疗科技有限公司 Il‑8单独或与其他细胞因子联合在治疗肝纤维化中的用途
CA3044526A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183931A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3919906A4 (en) * 2019-01-31 2022-11-09 Sekisui Medical Co., Ltd. METHODS FOR IMMUNOLOGICAL ANALYSIS OF FREE TARGETS IN A BIOLOGICAL SAMPLE AND METHODS FOR DETECTING NASH IN A SUBJECT
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
JPH07502019A (ja) * 1991-08-06 1995-03-02 シェリング・コーポレーション 内毒素または超抗原に誘導された毒性を治療するインターロイキン−１０類似体またはアンタゴニストの使用
NZ249754A (en) * 1992-03-04 1997-06-24 Schering Corp Interleukin-10 and its use in inhibiting graft vs host disease or tissue rejection
CA2085291A1 (en) * 1992-07-30 1994-01-31 Martin L. Breitman Novel receptor tyrosine kinase
CA2142861C (en) * 1992-08-20 2000-08-15 Robert Coffman Novel uses of il-4 and/or il-10, and antibodies against the same
AU681178B2 (en) * 1993-07-26 1997-08-21 Schering Corporation Agonists and antagonists of human interleukin-10

Also Published As

Publication number Publication date
US6168791B1 (en) 2001-01-02
DE69518156T2 (de) 2001-01-11
DK0769054T3 (da) 2000-11-13
HU220344B (hu) 2001-12-28
RU2218348C2 (ru) 2003-12-10
CN1216992C (zh) 2005-08-31
GR3034628T3 (en) 2001-01-31
US6159937A (en) 2000-12-12
UA57702C2 (uk) 2003-07-15
US6599501B1 (en) 2003-07-29
NO970020L (no) 1997-03-05
EP0769054A1 (en) 1997-04-23
NO970020D0 (no) 1997-01-03
EP0769054B1 (en) 2000-07-26
HK1012416A1 (en) 1999-07-30
CN1159830A (zh) 1997-09-17
FI970009A (fi) 1997-03-04
PL319429A1 (en) 1997-08-04
EE03451B1 (et) 2001-06-15
AP690A (en) 1998-10-16
AU2612195A (en) 1996-01-25
MX9606537A (es) 1997-12-31
PL181042B1 (pl) 2001-05-31
WO1996001318A1 (en) 1996-01-18
BR9508243A (pt) 1997-10-21
EE9700029A (et) 1997-08-15
JPH10502249A (ja) 1998-03-03
CZ1497A3 (en) 1997-05-14
SK283096B6 (sk) 2003-02-04
HUT76673A (en) 1997-10-28
RO118758B1 (ro) 2003-10-30
ATE195003T1 (de) 2000-08-15
AU686816B2 (en) 1998-02-12
FI970009A0 (fi) 1997-01-02
CA2194444C (en) 2003-01-14
CA2194444A1 (en) 1996-01-18
DE69518156D1 (de) 2000-08-31
AP9700962A0 (en) 1997-04-30
NZ287406A (en) 1998-07-28
EP1013764A1 (en) 2000-06-28
SK161496A3 (en) 1997-08-06
PT769054E (pt) 2000-11-30
HU9603615D0 (en) 1997-02-28

Similar Documents

Publication Publication Date Title
ES2148525T3 (es) Inmunomoduladores.
Lotz et al. Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies.
Megha et al. Cascade of immune mechanism and consequences of inflammatory disorders
Zourbas et al. Localization of pro-inflammatory (IL-12, IL-15) and anti-inflammatory (IL-11, IL-13) cytokines at the foetomaternal interface during murine pregnancy
Doyle et al. Comparison of the biological activities of human recombinant interleukin-2125 and native interleukin-2
Hill et al. Products of activated lymphocytes and macrophages inhibit mouse embryo development in vitro.
DE69428992D1 (de) Immunologische verbesserung mit intermittierender interleukin-2 therapie
SE9000532D0 (sv) Farmaceutisk tclf-komposition
Cohen et al. Autocrine and paracrine regulation of human T cell IL-10 production.
ECSP045297A (es) Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn?
Tuo et al. Upregulation of interleukin-4 and IFN-gamma expression by IFN-tau, a member of the type I IFN family
Panzer et al. Interaction of IL‐1β, IL‐6 and tumour necrosis factor‐alpha (TNF‐α) in human T cells activated by murine antigens
Flores-Romo et al. Soluble fragments of the low-affinity IgE receptor (CD23) inhibit the spontaneous migration of U937 monocytic cells: neutralization of MIF-activity by a CD23 antibody.
Tamatani et al. Existence of both IL-1 alpha and beta in normal human amniotic fluid: unique high molecular weight form of IL-1 beta.
Herman et al. Prostaglandin E2 depresses natural cytotoxicity by inhibiting interleukin-1 production by large granular lymphocytes.
Thurman et al. Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations
Sosroseno et al. The interleukin network in the immunopathogenesis of oral diseases
Adamik et al. Immunological status of septic and trauma patients. II. Proliferative response and production of interleukin 6 and tumor necrosis factor alpha by peripheral blood mononuclear cells from septic survivor, nonsurvivor and trauma patients: a correlation with the survival rate
Modéer et al. Phenytoin induces interleukin-1 production in vitro
De La Barrera et al. NK cells modulate the cytotoxic activity generated by Mycobacterium leprae-hsp65 in leprosy patients: role of IL-18 and IL-13
Talmadge Development of immunotherapeutic strategies for the treatment of malignant neoplasms
Venkataraman et al. Radiation causes increased production and decreased utilization of IL-2 in human mononuclear cells
Higgins et al. Interleukin-1 Inhibitors and Their Significance in Rheumatoid Arthritis
Ohta et al. Thymosin-α1 Increases the Capability to Produce Interleukin-3 but Not Interleukin-2 in nu/nu Mice
Sfaksi et al. Cellular immune response in rnu/rnu rats. I. Lectin responsiveness and IL-2 production kinetics of natural cytotoxicity and spleen-cell surface marker expression.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 769054

Country of ref document: ES